Market access expert Colin Wight details ten key considerations for investors in biotechnology and biopharma. He notes that implementing a well-rounded market access strategy should begin at the early stages of the research pipeline and that the final product’s price should be based on its value.
“Contrary to what many believe, market access is not a ‘late stage’ activity – it starts as soon as you enter the clinic, as this is when you start to shape the value of the asset. Market access planning is a core part of strategic drug development & runs parallel to clinical development.” Read more here.
(Source: Colin Wight, 5/17/21, LinkedIn)